Asthma

References

• Global Strategy for Asthma Management and Prevention, Updated 2019. ginasthma.org/gina-reports.
   Google Scholar
• Boulet LP, Reddel HK, Bateman E, et al. The Global Initiative for Asthma (GINA): 25 years later. Eur Respir J. 2019;54(2):1900598. Aug 29. doi:10.1183/13993003.00598-2019.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3): 1701103. Sep 9. doi:10.1183/13993003.01103-2017.
   PubMed Web of Science ®Google Scholar
• Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. Jun 27. doi:10.1183/13993003.01046-2019.
   PubMed Web of Science ®Google Scholar
• Papi A, Canonica GW, Maestrelli P, BEST Study Group, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040–2052. May 17. doi:10.1056/NEJMoa063861.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018; 378(20):1865–1876. May 17. doi:10.1056/NEJMoa1715274.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018; 378(20):1877–1887. May 17. doi:10.1056/NEJMoa1715275.
   PubMed Web of Science ®Google Scholar
• Beasley R, Holliday M, Reddel HK, Novel START Study Team, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. May 23. doi:10.1056/NEJMoa1901963.
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, PRACTICAL study team, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928. Sep 14. doi:10.1016/S0140-6736(19)31948-8.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. Eur Respir J. 2020;55(1):PMID3158662. doi:10.1183/13993003.00588-2019.
   Google Scholar
• Cockcroft DW, Davis BE, Blais CM. Thunderstorm asthma: An allergen-induced early asthmatic response. Ann Allergy Asthma Immunol. 2018;120(2):120–123. Feb. doi:10.1016/j.anai.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Domingo C, Rello J, Sogo A. As-needed ICS-LABA in mild asthma: what does the evidence say? Drugs. 2019;79(16):1729–1737. Nov. doi:10.1007/s40265-019-01202-0.
   PubMed Web of Science ®Google Scholar
• Amirav I, Newhouse MT. The most fundamental change in asthma management in 30 years? Eur Respir J. 2019;54(5):PMID31249014. Nov 21. doi:10.1183/13993003.01583-2019.
   Web of Science ®Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–1484. Apr 10. doi:10.1001/jama.2018.2757.
   PubMed Web of Science ®Google Scholar
• Casale TB, Aalbers R, Bleecker ER, et al. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. Respir Med. 2019;158:97–109. Sep 30. doi:10.1016/j.rmed.2019.09.014.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. Nov 9. doi:10.1016/S0140-6736(19)32215-9.
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Krishnan JA, King TS, et al. National Heart, Lung, and Blood Institute AsthmaNet. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2019; 380(21):2009–2019. May 23. doi:10.1056/NEJMoa1814917.
   PubMed Web of Science ®Google Scholar
• Wong G. How should we treat patients with mild asthma? N Engl J Med. 2019; 380(21):2064–2066. May 23. doi:10.1056/NEJMe1905354.
   Web of Science ®Google Scholar
• Edris A, De Feyter S, Maes T, et al. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. Aug 8. doi:10.1186/s12931-019-1138-3.
   PubMed Web of Science ®Google Scholar
• Walker BL, Leigh R. Use of biologics as immunotherapy in asthma and related diseases. Expert Rev Clin Immunol. 2008;4(6):743–756. Nov. doi:10.1586/1744666X.4.6.743.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. Jun 28. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2019; Sep 12. doi:10.1016/j.jaip.2019.08.050.
   Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. Nov 2. doi:10.1016/SO140-6736(19)31881-1.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and cormobid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447–2449.e2. Sep-Oct. doi:10.1016/j.jaip.2019.03.023.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Busby J, Bradding P, et al. Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454–464. Feb 15. doi:10.1164/rccm.201806-1182OC.
   PubMed Web of Science ®Google Scholar
• Settipane RA, Kreindler JL, Chung Y, et al. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019;123(6):564–572.e3. Dec. doi:10.1016/j.anai.2019.008.462.
   Web of Science ®Google Scholar
• Chen W, Safari A, FitzGerald JM, et al. Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax. 2019;74(12):1113–1119. Dec. doi:10.1136/thoraxjnl-2019-213223.
   PubMed Web of Science ®Google Scholar
• Yaghoubi M, Adibi A, Safari A, et al. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112. Nov 1. doi:10.1164/rccm.201901-0016OC.
   PubMed Web of Science ®Google Scholar